Introduction
What biochemical processes are involved in mental depression? Is there a biochemical trigger that sets in motion a process developing into mental depression? Is there a deficiency or excess of some chemical substance that is responsible? We know that chemical and physical factors are involved in some manner in depression because of the efficacy of drug therapy and of electroconvulsive therapy. But how do these treatments work? Do the chemical changes that they generate help us to understand the underlying chemical processes in mental depression?
Three major areas of biochemistry have been explored with the production of some significant facts for the understanding of the biochemistry of mental depression (17, 99) . The first deals with the role of ions and their exchanges during nerve transmission. This has focused some attention on cationic balance in mental depression. The use of radioactive sodium has facilitated some complex measurements indicating that a certain portion of body sodium stored intracellularly together with a portion of that in bone is increased in depression and mania, but returns to normal after recovery (89) . The conclusion is based on derived data and is not readily interpretable in terms of the changes seen during the development and treatment of mental depression. However, alterations in the sodium balance may represent an underlying process of the disorder. Can. Psychiatr. Assoc. J. Vol. 22 (1977) The second thrust of biochemistry has been the search for hormonal changes characteristic of mental depression. This has generated considerable research material in the past. The role of the adrenal cortex has been of interest because of the implied increase that might stem from greater intrapsychic stress. If the adrenal cortex displays greater activity in mental depression, this implies greater activity of the pituitary with secretion of ACTH, greater release of CRF (corticotropin releasing factor), and increased activity of more remote mechanisms that regulate the release of CRF. Presumably there are different pathways for initiating the release of CRFdifferent qualities of stressful events impinging upon the individual from the outside, or originating in proprioceptive or intracerebral events. However, we still do not know what these are. The reported frequent increase in adrenal cortical activity in depressed patients (12, 19, 26, (75) (76) (77) (78) has been invoked in various theories of depression.
Recent reports by Prange and his collaborators have suggested that the administration of thyroid hormone potentiates the action of tricyclic antidepressants (68) . The general retardation of the hypothyroid individual makes such reports attractive, but they require confirmation from other clinics. The increase in serum thyrotropin (TSH) in response to the administration of its releaser TRH (TSH-releasing hormone, protirelin, pyroglutamyl-histidyl-prolinamide) appears to be subnormal in depressives (41, 42, 49, 69) . Gold et al. (37) state that the TSH response is greater in the bipolar depressed patient than in the manic. The intravenous administration of TRH is re-ported to have a rapid, partial, brief and beneficial effect in women with unipolar depression (41, 49, 69) . Another hypothalamic hormone, melanocytestimulating hormone-release inhibiting hormone (MRIH-I, prolyl-leucyl-glycinamide), has also been tested in depressive women (29) , but requires more extensive testing before its value can be determined.
Currently the most popular and productive hypotheses regarding mental depression deal with the possibility of changes in the balance of neurotransmitters at important synaptic junctions in the brain or of specific functional deficits of neurotransmitters. Among the many candidates for the title of neurotransmitter, acetylcholine alone has met the most fastidious requirements of the physiologists for proof of its function in this capacity. Others receive the title gratuitously while awaiting final proof. Out of the welter of compounds that have been proposed as neurotransmitters, two catecholamines, dopamine and noradrenaline, and the indoleamine 5-hydroxytryptamine (5HT, serotonin) have been vigorously promulgated in hypotheses that attempt to characterize chemical imbalances in mental depression. These amines have been localized in specific regions of the brain and neuronal tracts of experimental animals by means of histofluorescence techniques, methods that have even been extended successfully to human brain obtained post mortem (61) . The monoamines are synthesized in specific neurons in the brain and elsewhere; they accumulate in vesicles at the nerve endings (the beaded terminations that represent presynaptic sites); and are released during neuronal activity. Following release the amine transmitter diffuses across the synaptic cleft to the postsynaptic surface of another appropriate neuron where it combines temporarily with a receptor and initiates neuronal activity in the second fibre. After dissociating from the receptor the amine is metabolized locally or else is taken up into the presynaptic termination where it can be stored once more for future use. The return passage to terminals of the neuron which released the amine may also involve stimulation of presynaptic receptors, or autorecep-tors (receptors anywhere on the neuron that respond to its own transmitter product). Autoreceptors may play a role in regulating the physiological activity of the neuron and the rate of synthesis of its transmitter. Thus, the nerve ending embodies many mechanisms relating to the biosynthesis, storage, release, re-uptake and metabolism of monoamines. These properties have been studied extensively in synaptosomes, or broken-off nerve endings, which neurochemists prepare from brain tissue (98, 99) , including human brain (104) .
Many functions of nerve endings, as represented by synaptosomes are mimicked by blood platelets, and some investigators regard the platelet as a useful model of nerve endings (55, 62, 65) , easily accessible for experimental purposes. For example, the rapid, energy-requiring (active) transport system whereby transmitters are swept back into the nerve ending after working their function on the postsynaptic region can also be found in the platelet membrane, and is even said to be deficient in regard to the uptake of 5HT in depressed patients (103) . Under physiological circumstances nerve endings contain extremely high concentrations of transmitter amines, but these are pharmacologically inactive because they are encased within the specialized membrane of the storage vesicle, and exert biological activity only after they escape into the synaptic cleft. This storage facility is readily apparent in platelets as well.
Monoamine Oxidase
With the discovery that certain effective antidepressant agents strongly inhibit monoamine oxidase (MAO), there has been a great emphasis on the study of this enzyme in brain and platelets, and its possible relationship to mental depression. Robinson and his colleagues have shown that, apart from the early years of life, brain MAO activity increases with age (71-73; cf.38). This finding is consistent with the concept of a decrease of one or more transmitter monoamines with increasing age, and furthermore correlates well with the increasing incidence of depression with advancing years. Furthermore, these investigators have shown that women have higher MAO activity in the brain than men (73) , again consistent with the greater incidence of depression in females. Both forms of MAO (types A and B based on sensitivity to certain inhibitors) are present in human brain; their relative activities vary little from region to region (87) .
The age factor is also seen to some extent in regard to platelet MAO (71) . Perhaps of greater importance is that there are genetic factors affecting the concentration of MAO in platelets (58, 112) . It is not known if brain MAO is similarly influenced, or whether these genetic factors are at all related to the genetic component in mental depression as suggested by response to drugs (63), by clinical-therapeutic studies (28) , or epidemiological investigations in Iowa, Scandinavia and elsewhere (102) , but this is obviously an important area for future exploration in biochemical psychiatry. There is at least one study of brain MAO that indicates that the concentration of the enzyme is not significantly different in depressive suicides from controls (38) . Another, based on indirect evidence, suggests that mental depression entails an increase in (peripheral) MAO activity (80) .
Does measurement of platelet MAO actually tell us anything about mental depression? First of all, it is subject to the action of MAO inhibitors just as the enzyme elsewhere in the body. It tends to be slightly higher in females (71) , as has been shown for brain (73) . In bipolar depressives the mean concentration of platelet MAO is only about half the value found in controls (44, 57) . This difference is not apparent in the unipolar depressives. Despite this interesting group comparison these investigators did not find a correlation between the clinical state of a patient and the concentration of MAO in the platelets.
To summarize about MAO, there is assurance that MAO is important in mental depression and recovery from it, but its specific role in the balance of mental activities remains to be worked out. This may not be an easy task because the inhibition of MAO initiates multiple actions that reverberate well beyond the accumula-tion of monoamines which now cannot undergo oxidation.
Catechol O-Methyltransferase
Other enzymes have been studied in the search for correlatives or biochemical identifiers of affective disorder. Gershon and Jonas have suggested, on the basis of erythrocyte COMT measurements in depressed patients and members of their families, that this enzyme is a "marker of genetically determined vulnerability to affective illness" (32) . The ill probands with erythrocyte COMT activity greater than the controls had higher values of the enzymic activity than did their healthy relatives, but this did not hold true for families in which the patient had lower COMT activity than in controls. There is some evidence of a reduction in this enzyme in women with affective disorder, but not in men (16) . The women with unipolar depression had the lowest mean value for the activity of erythrocyte COMT (27) .
Monoamines
For many years there have been several actively promulgated "amine hypotheses" of mental depression attributing the abnormal effect to a deficiency of biogenic amines generally (5), or to a decreased sensitivity of receptors to these amines (52) . Some hypotheses have invoked the concept of a catecholamine deficiency (81, 84, 86, 88, 95) , especially a deficiency of noradrenaline, in that disease (81, 86, 88) . Dopamine did not receive as much attention, but in recent years it has been considered because of tests of L-dopa in mental depression based upon the anti-akinesic action of this amino acid in patients with Parkinson's disease. There have also been hypotheses centering upon serotonin, again with many investigators fostering them (2, 18, 24, 45) . Van Praag and his colleagues have regarded both noradrenaline and serotonin at fault in depression. Although these investigators have judged the condition to stem from a noradrenaline deficiency (l05, 109) their view of the role of serotonin has changed over the years. Currently they propose that there are two types of endogenous depression, and these would stem from central serotonin and noradrenaline deficiencies, respectively. The subtypes cannot be differentiated in psychopathological terms but ought to respond to different treatments. Van Praag's evaluation of the role of monoamines in depressive disorders (105) provides an excellent summary of many of these problems from the point of view of the clinician.
There are great difficulties in the path of the investigator who wishes to determine whether, during the course of mental depression or in the manic phase of manicdepressive psychosis, there is an actual deficiency of one or more amines. The best data would come from kinetic measurements of the rates of utilization of the compounds in the brain during the life of the individual, indeed, during the display of both normal and abnormal affective behaviours. At the present time there are no methods for such chemical measurements on the brain without the use of impermissible invasive and deleterious procedures: there is no instrument available for the chemistry of the brain that does what the EMI scanner provides for the neurosurgeon. Some investigators have been able to obtain brain tissue post mortem from subjects who died in a state of depression. Others have sampled metabolites in the eSF during life. With the knowledge that MHPG is a predominantly cerebral metabolite of noradrenaline, some investigators have followed the excretion of this compound in the urine. But the great clues about monoamine mechanisms in depression have come from the use of drugs in treatment and the examination of the biochemical and clinical effects of those drugs, and the pharmacological mode of investigation still stands everyone in good stead.
Noradrenaline
Robinson and his colleagues (70,72) have measured the concentration of noradrenaline in the hindbrain of 55 patients and have been able to demonstrate that decade by decade the concentration of this amine decreases. The finding is consistent with the increasing concentration of MAO in the brain with age. However Moses and Robins (53) , in an investigation of depressives who committed suicide, detected few differences in concentration of noradrenaline from brains of patients dying from non-mental, nonneurological diseases, and these changes were not regarded as important. Such findings do not necessarily exclude noradrenaline from a role in depression, because of regulatory and compensatory mechanisms that operate to maintain a fairly steady concentration of the amine in the brain. A more (or less) rapid rate of utilization of this might not even be detectable by measuring the concentration of the amine.
The organic product resulting from the action of MAO is an aldehyde, whose presence in tissue is usually evanescent because of its rapid metabolism by way of further oxidation (dehydrogenation) with formation of an organic acid, or reduction to an alcoholic derivative. The terminal products of metabolism of the biogenic amines are HV A (homo vanillic acid) from dopamine; 5HIAA (5-hydroxyindoleacetic acid) from serotonin; and VMA (vanillylmandelic acid) from noradrenaline. VMA is the predominant terminal metabolite of noradrenaline .outside the central nervous system; in the brain this amine undergoes metabolism to a neutral, glycolic compound known as MHPG (3-methoxy-4hydroxyphenylglycol). MHPG eventually is excreted in the urine and some investigators are attempting to determine the extent to which this urinary metabolite reflects turnover of noradrenaline in the eNS. The metabolites HVA, 5HIAA and MHPG can be detected in the brain and eSF. Their measurement in eSF has occupied a great deal of attention in the last few years, for, if their concentration in the eSF reflects turnover or rate of utilization of the monoamine in the brain, then there might be a further relationship of the level of the metabolite to the clinical picture. It has been hypothesized that this could even provide some understanding of which monoamine transmitters are important in the evolution of psychiatric syndromes. The metabolites are present in the blood but only en passage, and the concentrations there are minute.
Goodwin (34) found that the concentration of MHPG in the eSF of bipolar depressed patients was lower than in unipolar depressed patients, or in a series of controls. Because some noradrenaline-containing fibres of brain and spinal cord are now known to play an important role in motor activity, changes in the chief metabolites of this compound in the CNS might merely reflect the fact that the depressive patient engages in less activity. However, even when this is taken into account, the mean MHPG concentration in the lumbar CSF of depressed patients seems to be subnormal.
One of the pharmacological models of depression is that induced by reserpine. This drug leads to a reduction in the concentrations of many of the protagonist monoamines that we are speaking about, so that it would be difficult to assign responsibility for the biological and behavioural actions of reserpine to a particular one. It is well known that the reserpinized state can be temporarily overcome by the administration of L-dopa (the precursor of catecholamines). The injection of dopa leads to a very large increase in the concentration of dopamine in the brain which persists for a shorter or longer time, and a small increase in the concentration of noradrenaline. Clinical trials with orally administered dopa in depressive patients, in any case, have had very little success (35) , so that even the increased brain dopamine which provides an anti-akinetic effect in Parkinson's disease does not have any pronounced antiretardation effect in mental depression.
A hydroxy derivative of dopa, namely dops or 3,4-dihydroxyphenylserine, is an immediate precursor of noradrenaline, though one that does not occur in mammals. The conversion of synthetic dops to noradrenaline takes place very slowly, at least in experimental animals. The compound does not seem to have been tried yet in humans.
If mental depression were due to a deficiency of noradrenaline, then a reduction in its concentration in the brain might induce the depressed state, or exaggerate it if there were a pre-existing depression. The most commonly used means now for reducing catecholamine concentrations in the tissues is the administration of alpha-methyltyrosine, When this drug was added to the tricyclic anti-depressant with which patients were being successfully treated, Shopsin (94) found no effect on the well-being of the patient. This signifies that the imposition of an inhibitor of catecholamine biosynthesis does not materially interfere with imipramine treatment of depression. If under the conditions used the alpha-rnethyltyrosine were affecting dopamine concentrations but not noradrenaline one might still miss a role for noradrenaline in the mechanism of depression. For this reason Sack and Goodwin (79) tested fusaric acid, an inhibitor of dopamine beta-hydroxylase (DBH), the enzyme that is responsible for catalyzing the conversion of dopamine to noradrenaline, and whose inhibition leads to a lowering of the concentration of noradrenaline in the tissues. They found that this drug aggravated the condition of manic patients who had been taken off their anti-depressive medication. The serum DBH concentration is not abnormal in affective disease (92, 110) .
As for the urinary output of MHPG, the noradrenaline metabolite of the nervous system, Schildkraut (83, 85) , Maas and his colleagues (25, 50, 51) , and Casper et al. (13) , claim that it is excreted in abnormally low amounts in depressed patients. This is all the more interesting because in some studies other catecholamine metabolites measured at the same time, such as metanephrine, normetanephrine and VMA, were present in the usual amounts. However not all published results support this argument (82, 94) . The urinary concentration of MHPG has been investigated from still another standpoint, namely, its correlation with changes in mental state during the course of treatment. There have been some claims for the predictive value of urinary MHPG, to the effect that a low MHPG value is associated with improved status on an imipramine regime (8, 51) , a high value with failure. The low-MHPG patients, as a group, did not respond well to amitriptyline (8), but those excreting normal or elevated amounts of MHPG in the urine tended to improve with this anti-depressant drug (82) . An interesting feature about the predictive correlation is that imipramine, for which a correlation holds, has a perisynaptic action that retards the re-uptake of noradrenaline from the synaptic cleft into the pre-synaptic nerve ending. On the other hand amitriptyline, for which the correlation was not apparent, preferentially inhibits the uptake of serotonin. There is a suggestion here of bimodality of origin of the depressive state.
In assessing a possible role of noradrenaline in mental depression it is clear that some of the biochemical evidence suggests that a relationship exists. The MHPG determinations would favour this, but do not offer very strong evidence because of some inconsistencies among investigators. Urinary MHPG may be useful as an indicator of which tricyclic antidepressant to use; this deserves further research, although it is obvious that many factors affect the outcome of treatment. The experiment with alphamethyltyrosine excludes at present a critical role for noradrenaline in the mechanism of endogenous depression or its response to successful treatment with imipramine (94).
Dopamine
As with noradrenaline there are no significant changes in the concentration of dopamine in various parts of the brain in depressive suicides (53) . There is an indirect piece of evidence from neuroendocrinology pointing to deficient dopaminergic mechanisms in the hypothalamus of depressed patients. Hypoglycemia calls these mechanisms into play with a resultant increase in secretion of growth hormone, but the response is subnormal in depression (13) .
In regard to the concentration of HVA in eSF drawn from the lumbar space, Post and his colleagues (67) have made an extensive compilation of studies. If one selects from these only those investigations which included suitable control groups, and then pools the results, there seems to be a subnormal mean concentration of HVA in depressed patients as compared with a variety of controls that have been used. On closer examination of the results this conclusion is true only for a few of the studies. Thus, depressives are considered slightly lower in regard to eSF-HVA than controls (60), or definitely lower (96) by some investigators but not significantly different from controls by others (36, 106, 107) . Hence, without knowing more about the selection of patients in the different clinics one cannot fairly draw a conclusion that HVA is present in subnormal amounts in the eSF of depressive patients.
The concentration of this metabolite at any given time is a balance between (a) the rate of metabolism of dopamine in the brain; (b) the entry of HVA into the eSF; and (c) the removal by an active transport mechanism of the HVA. The removal mechanism can be inhibited by probenecid, and if normal subjects are given enough of this drug the level of acidic metabolites like HVA and 5HIAA can be expected to rise appreciably over a short period of time, as they continue to be formed and enter the eSF. A large rise in HVA following probenecid might signify active turnover of dopamine, whereas a small increase, as is seen in Parkinson's disease, might signify only low concentration of the precursor amine in nervous tissue, or its very low turnover rate there. Post and Goodwin (66) have studied patients with the probenecid test very extensively and, while the baseline concentrations of HVA are not abnormal among manic-depressive and hypomanic patients, the rate of increase of HVA during probenecid administration is certainly below normal. This is a fairly consistent finding by groups in Sweden (60,74,96,97), the Netherlands (106,107) and the United States (36, 66) .
Such studies indicate that there may be a deficiency of dopamine or of the mechanisms for its production in a state of mental depression but it is still necessary to determine the extent to which motor retardation of the patients contributes to the low values (ef. 66). Of course, the experiment of Shopsin and his colleagues with alphamethyltyrosine in successfully treated depressive patients, referred to earlier, also shows, because of the blocking action of the drug generally on synthesis of catecholamines, that interference with dopamine production need not cause a deterioration of these patients' condition. On the other hand, Murphy and his colleagues found that giving L-dopa to patients with bipolar depression usually induces hypomania (54) .
Various drugs used in the treatment of mental depression seem to have little or no effect upon the accumulation of HVA in the probenecid test. Electroconvulsive therapy does not affect the concentration (60).
In assessing a possible role for dopamine in mental depression it is clear that dopa as a drug is effective only in a few retarded depressed patients. Experimental work shows that the tricyclic anti-depressants have little effect on the uptake of dopamine and one could not expect their action to be mediated by this monoamine centrally. Interference with the production of catecholamines, including dopamine, has no effect on the well-being of treated depressives. Measurement of HVA concentrations in the CSF has been of limited help: the HVA does not seem to rise as fast after probenecid treatment as in controls, but its concentration is not lower than in the control resting patient. The HVA levels are affected by motor activity. Probably dopamine plays a role in the motor component of mental depression.
Two new factors may aid in determining the importance of dopamine in depression. I) The introduction of nomifensine into the field, a drug with somewhat selective action in stimulating dopamine receptors, may help to accumulate information of a new kind about the role of dopamine in depression. 2) Stemming from the supersensitivity ofreceptors to "their" transmitter that is observed experimentally in denervated preparations, one can expect to find tests of this function being developed for studies in man. If there is deficient transmitter function, then understimulated receptors in the brain might prove to respond more readily than normally to appropriate agonists. This has been claimed for the dopamine-mediated release of growth hormone in bipolar depressed patients, as compared with unipolar patients, when these have been treated with L-dopa, the precursor of dopamine. In fact, the result has also been said to obtain for the dopamine-mediated suppression of prolactin section (37) .
Serotonin
For some years there has been accumulating evidence that either serotonin or its chief metabolite 5HIAA, or both, are low in certain regions of the brain of depressives and of suicide cases. Shaw et al. (90) reported low concentrations of 5HT in hindbrain of suicides; Pare et al. (64) noted this in the brainstem; and Lloyd et al. (48) in certain of the raphe nuclei (the chief sites of synthesis of 5HT in the brain). Bourne et al. did not find differences for 5HT, but noted that its chief metabolite 5HIAA was lower in the hindbrains of suicidal patients (10) . Lloyd et al. (48) found normal 5HT concentrations in the higher parts of the brainstem and in the telencephalon, and somewhat higher amounts of 5HIAA in some of the limbic structures. Cochran et al. (15) saw no changes in 5HT levels in various regions of the brain in suicidal patients.
There is always the caveat in this kind of research that the brains of the index group must be obtained under the same conditions as far as possible and with no greater delay following death than the control group. Important as this is, one should recognize that following the cessation of respiration the brain becomes anoxic almost instantaneously -there is essentially no reserve of oxygen in that organ -so that monoamine oxidase becomes essentially inoperative. Furthermore, other catabolic enzymes may be quite limited in their action. For example, COMT requires S-adenosylmethionine as its cosubstrate, but this material can be formed only with the input of energy, and that energy must come from respiratory processes; anerobic glycolysis (which might continue after death) is rather inefficient in the production of ATP. Finally, death entails loss of temperature control so that brain temperature falls and with it the rate of enzyme action. These considerations are mentioned in order to point out the abiding usefulness of post mortem brain measurements, as long as the brains are collected and treated with dispatch.
As with HVA many studies, including those with control series, have been carried out to measure 5HIAA in lumbar CSF. The results of these studies are by no means consistent (cf. Table I, reference 67), and it is not possible to conclude from them that the 5HIAA concentration is subnormal in depressives. The probenecid test has been applied to depressed patients also. The accumulation of 5HIAA with time following administration of probenecid is somewhat lower in the affective psychoses (36, 60, 74, 96, 107) . Asberg measured the 5HIAA concentration in the CSF of 68 depressed patients, some of whom attempted suicide (3) . Her values demonstrate that this measurement is distributed bimodally, a feature especially marked in the endogenous depressed group (l,2). In those with less than 15 ng of 5HIAA per ml there was a significant correlation between the severity of the depression, according to a rating scale, and the concentration of 5HIAA. There was no correlation for the high 5HIAA group, that is, with CSF amounts greater than 15 ng per ml. In the low 5HIAA group there was a significant excess of suicide attempts (and these were of the more aggressive type). Asberg's bimodal distribution may well explain the difficulties of investigators in establishing significant differences in the levels of monoamine metabolites in the CSF, with or without probenecid. If a patient group really includes two kinds with different modal values, and if these are pooled, there would be little hope of detecting differences even when one of the groups is distinctly different from controls. Goodwin (34) claims that the accumulation of 5HIAA after probenecid also shows a bimodal distribution of values, even in medication-free hospitalized depressed patients. He states that the low 5HIAA subgroup is significantly different from the high subgroup in respect to having a higher proportion of females, later age of onset of depression, higher urinary MHPG, and poor response to imipramine but good response to amitriptyline.
Van Praag (l05) also conceives ofbimodality in the chemistry of depression, perhaps characterized by whether there is a central deficiency of 5HT or not (108) . In therapeutic trials with clomipramine he found eight patients who did not respond. They were then "washed out" and changed over to nortriptyline, the manoeuvres being carried out without the patients' knowledge. Five of the eight patients then showed improvement, but there was no correlation with MHPG levels. Again this was suggestive of a second type of depressive patient. Kripke (43) contends that bimodal distributions need not be postulated until one has ruled out the possibility that a diurnal rhythm has been shifted out of place.
Murphy et al. (56) examined the responses to fenfluramine. In low doses this drug serves as a serotonin agonist; it also blocks the uptake of serotonin and reduces its turnover. In ten patients receiving a median dose of 120 mg of fenfluramine daily there was improvement in the depression rating in a majority of the bipolar depressives after a few weeks of treatment but not so in the unipolar cases.
If 5HT deficiency plays a role in mental depression, then the production of such a deficiency ought to entail an altered effect, and relief of the deficiency by provision of 5HT precursors ought to re-establish the normothymic state. In fact, there are natural and iatrogenic states that seem to involve 5HT deficiency, and these cause mental depression. The effect of reserpine has already been mentioned; this, of course, does not lead to a specific 5HT-deficiency, but the reduced amount of 5HT in the brain probably contributes to the depressive state. The treatment of Parkinson's disease patients with L-dopa sometimes causes depression, and this has been attributed to interference with the intestinal absorption of tryptophan by competition between the two amino acids (47) or to the excessive formation of dopamine in the brain which depletes the 5HT from its storage sites (9) . The administration of tryptophan corrects the condition (9) . There are "natural" diseases causing 5HT depletion, such as the carcinoid syndrome and regional enteritis, and in these depression is relieved by tryptophan (39, 46) .
Tryptophan has by this time been tested in many patients with endogenous depression. Some studies report success, others failure. The therapeutic trials have been of mixed quality, carried out with different diagnostic criteria, different doses of tryptophan, various dose-schedules, and for varying periods of time. There is no consensus on the efficacy of tryptophan in depression.
Likewise, the administration of 5-hydroxytryptophan ought to be useful for the same purposes as tryptophan in making up a cerebral deficiency of 5HT. However, there is a controversy at the present time about the efficacy of this amino acid (105). Shopsin's experiment (94) with alphamethyltyrosine in treated depressives was extended by use of para-chlorophenylalanine (93) . Depressed patients who were being successfully treated, some with imipramine and others with tranylcypromine, were given that amino acid in order to inhibit serotonin synthesis. Although the patients continued to receive their therapeutic medication, the drug caused them to revert to the morbid state, and its withdrawal permitted the re-establishment of mental well-being.
The evidence put forward for a role of 5HT deficiency in mental depression, while not without apparent contradictions, shows that subnormal concentrations of the amine or its metabolite 5HIAA in the brains of depressives are demonstrable under certain conditions. Moreover, 5HIAA in the CSF, if not different in its concentration from controls under resting conditions, may not be delivered as rapidly to the CSF in depressed patients, as shown in tests with probenecid. This can be interpreted as arising from a lower concentration of 5HT in the brain or a slower rate of its release and metabolism. The finding that treated patients deteriorate under the influence of parachlorophenylalanine points to an important role of 5HT, although it should be kept in mind that this inhibitor also has other effects than reduction of 5HT formation. In line with the notion of a special function of 5HT one may point to the ameliorative effect of tryptophan in certain types of depression. The action of tryptophan in endogenous depression is still a matter of controversy. Yet the uncertainty may not reside in an intrinsic inertness of the amino acid in this condition, but rather in the way tryptophan has been employed in the therapeutic studies, usually without regard to its biochemical pharmacology.
Tryptophan in Mental Depression
The relation of tryptophan to depression has been sought, first of all, in metabolic studies of patients. The non-albumin-bound tryptophan of serum, the portion most readily available for transport across the blood-brain barrier, is low in some studies (6, 21) , but not in others (59, Ill) . The significance of CSF tryptophan is also a matter of dispute; reports give the concentration as low (20) or normal (4) . Some investigators, seeking more dynamic measures of tryptophan imbalance in depressives, have claimed that the flux of the amino acid from plasma to the cellular pool (where metabolism occurs), is reduced in depression (91, 101) .
The basis for the testing of tryptophan in mental depression is that serotonin is one of the amines whose concentration in the brain can be affected by peripheral events. When the tryptophan concentration in the brain increases, so does the serotonin level, and the tryptophan concentration is itself regulated peripherally (30, 31, 33, 114) . The level of tryptophan is subject to the action of the enzyme pyrrolase, which is found mainly in the liver, although the role of the small amounts in brain is just now being evaluated. The activity of this enzyme increases when large amounts of tryptophan reach the liver or when there is an increased input of corticoids as in stressful situations (22, 114) . Because of these inductive effects, which operate to one extent or another in the various clinical therapeutic trials of tryptophan, it is possible that the amount of tryptophan actually available for conversion at brain sites to 5HT may be quite variable, and unrelated to the actual dose of the amino acid taken by mouth. Curzon, some years ago, suggested the need for pyrrolase inhibitors as adjuncts in the treatment of mental depression (22) , that is to say, drugs that would protect tryptophan from degradation along the irreversible kynurenine pathway, and thus favour its passage to the brain where it can form serotonin. Among the proposed inhibitors are allopurinol (7) and nicotinamide, or nicotinic acid (113) . The effectiveness of allopurinol as a pyrrolase inhibitor in vivo is in doubt (23, 40) , but nicotinamide has now been used successfully in combination with tryptophan in a preliminary study from this laboratory (14) . Besides the use of nicotinamide to protect tryptophan from excessive degradation through the pyrrolase-catalysed kynurenine pathway, this trial made use of biochemical principles to avoid excessive levels of pyrrolase activity. Thus, relatively small amounts of tryptophan were used, and these were given in divided doses during the day in order not to induce pyrrolase excessively. Over a period of four weeks the 11 patients in the study showed significant improvement in the mean total scores for depression on both the Hamilton and the Beck rating scales. The plasma concentration of tryptophan was measured, and found to be much increased as a result of the tryptophan treatment. Other studies of the use of tryptophan in mental depression are now in progress, and it is hoped that the recognition of the biochemical factors affecting tryptophan utilization and availability for cerebral 5HT formation will permit an unequivocal judgment to be made about the efficacy of tryptophan in mental depression.
Conclusion
Despite the impressive amount of information obtained about monoamines in mental depression in the last fifteen years, (since these substances were first proposed as mediators involved in some way centrally in affective processes), there are still large gaps in the evidence even about the three chief protagonists: noradrenaline; dopamine; and 5-hydroxytryptamine. Investigators have built up arguments favouring one amine over the others; in more recent years there has been some relaxation of attitudes that tended to focus on one compound to the neglect of the others. As this paper has shown, there is evidence that the metabolism of all three of the amines can go awry in mental depression, perhaps not all the time and not in all types of depression, but that is a challenge for the next stage in biochemical and pharmacological studies of depression to expand upon. The evidence at hand is encouraging for the concept of some important involvement of a serotonin-containing pathway (or pathways), and clinicalbiochemical studies with its precursor tryptophan should prove helpful in delineating this role, as well as clarifying the interaction of serotonergic with other transmitter sys-tems. In the past, one of the major working hypotheses in regard to central neurotransmitter interactions has been that of Brodie,Spector and Shore (11). At the time of their proposal, they were concerned with the regulatory activity of noradrenaline and 5HT in the brain. These substances were postulated as the mediators of two opposing subcortical divisions, normally balanced against one another. Since then the concept has been extended as other putative neurotransmitters have become known so that "balance" is achieved, according to this view, by the convergence of opposing neurons at certain synaptic junctions or by some more complex interplay. However, experimental work with animals is making it very clear that many balances within the central nervous system are achieved through catenary control, that is to say, through the action of neurons connected to one another like links in a chain (100) . The application of this idea of catenary control to the problem of monoamine function in mental depression shows at once that it is not necessary to postulate a deficiency of one amine as against another, but rather there is the possibility of different biochemical forms of depression in which one or another link in the chain is weak. Then, specific means to increase the synaptic concentration of the corresponding transmitter would lead to amelioration of the condition, whereas increasing the concentration of another transmitter in the chain might merely represent a wasteful surfeit, without effect on the patient's mental functions. On this view also, the clinical manifestations of different deficiencies along the catenary system concerned with affective behaviour might all be very much the same, so that biochemicalpharmacological criteria would be essential to any advance in the field. This can be achieved only by more intensive laboratory investigations in the field of mental depression.
Resume
On tente dans cet article de decrire brievement les caracteristiques essentielles de la comprehension psychanalytique de la depression. L'introduction consiste en une courte discussion sur la psychanalyse, tant au point de vue theorique que pratique, suivie de la presentation de la litterature psychanalytique pertinente ala depression.
On a inclus dans cette revue, breve en raison de l'espace disponible, seulement les auteurs ayant le plus contribue a l' elaboration des theories de la depression au cours des annees ayant suivi l'oeuvre de pionnier d' Abraham et de Freud. On tente dans cette derniere section de souligner le developpement des formulations theoriques, du debut jusqu'a ce jour. Ce developpement revele la presence d'un nombre de themes qui persistent dans les formulations theoriques sur les malades deprimes, notamment l'oralite, 1'ambivalence, l'agression, la culpabilite et la regulation de 1'estime de soi. Sous plusieurs aspects, le developpement des theories psychanalytiques des depressions s' est fait parallelement au developpement de la theorie psychanalytique en general, depuis l'epoque de 1'analyse du ca, puis de l'analyse du moi, jusqu'a I'interet actuel pour le monde representatif de 1'individu. On presente un cas assez detaille, a la fois pour eclairer la section theorique de cet article et pour souligner Ie besoin d'etre prudent. dans l' application a un patient individuel d'une theorie preconcue. La complexite de la psychodynamique inherente achaque cas de depression est mise en relief.
